Aripiprazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aripiprazole: From Schizophrenia to Major Affective Disorder
One-Sentence Summary
Aripiprazole is a second-generation (atypical) antipsychotic with established global approval for schizophrenia and bipolar I disorder manic/mixed episodes. The TxGNN model predicts it may be effective for Major Affective Disorder (encompassing major depressive disorder and bipolar spectrum conditions), with multiple completed Phase 3 RCTs and 20 publications supporting this direction — including an existing FDA approval for adjunctive treatment of major depressive disorder that directly validates this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia; Bipolar I disorder (manic/mixed episodes) |
| Predicted New Indication | Major Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L1 |
| Saudi Arabia Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Aripiprazole acts as a partial agonist at dopamine D2/D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. This unique "dopamine stabilizer" mechanism allows it to simultaneously modulate dopamine-deficient states (depression) and dopamine-excess states (mania/psychosis) within the limbic system — making it mechanistically well-suited to a broad spectrum of affective disorders rather than a single diagnosis.
In treatment-resistant major depression (TRD), aripiprazole augments conventional antidepressants by enhancing prefrontal dopaminergic activity, addressing a component of depression that SSRIs and SNRIs do not fully correct. A dedicated PET/fMRI mechanistic study (NCT00953745, n=43) confirmed in vivo that this dopaminergic pathway is the primary mechanism of aripiprazole's antidepressant augmentation in TRD. The FDA subsequently approved aripiprazole as an adjunctive therapy for MDD in patients with inadequate antidepressant response — providing direct regulatory validation.
Major affective disorder encompasses both MDD and bipolar disorder, conditions sharing dysregulation of monoamine neurotransmission. Aripiprazole's transition from schizophrenia/bipolar mania indications to the broader affective spectrum is pharmacologically continuous and not merely predicted — it is supported by the largest body of Phase 3 RCT evidence among all atypical antipsychotics in this space.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00683852 | Phase 3 | Completed | 225 | Double-blind, placebo-controlled RCT of reduced-dose aripiprazole as adjunct to antidepressant therapy in MDD with inadequate prior response; core pivotal trial |
| NCT00876343 | Phase 3 | Completed | 586 | Aripiprazole vs placebo as adjunctive therapy co-administered with SSRI or SNRI in MDD; largest placebo-controlled efficacy and safety assessment |
| NCT00105196 | Phase 3 | Completed | 349 | 14-week RCT assessing aripiprazole adjunctive to open-label marketed ADT in MDD patients with incomplete 8-week antidepressant response |
| NCT02046564 | Phase 3 | Completed | 412 | Aripiprazole/sertraline combination (ASC-01) vs sertraline monotherapy in MDD with incomplete SSRI response; fixed-dose combination strategy |
| NCT01567527 | Phase 3 | Completed | 731 | 52-week double-blind RCT of aripiprazole IM depot as maintenance treatment in Bipolar I; primary endpoint: time to recurrence of any mood episode |
| NCT03423680 | Phase 3 | Recruiting | 390 | Therapeutic confirmatory study of aripiprazole adjunctive to mood stabilizer for major depressive episode in Bipolar I or II disorder (8-week double-blind) |
| NCT07153406 | Phase 3 | Not Yet Recruiting | 220 | Head-to-head: esketamine nasal spray vs aripiprazole both combined with SSRI/SNRI in elderly (>60 years) treatment-resistant MDD |
| NCT02960763 | Phase 4 | Completed | 742 | Comparative effectiveness of antidepressants in older adults with treatment-resistant depression; real-world outcomes |
| NCT01429831 | Phase 4 | Completed | 300 | Effectiveness and tolerability of aripiprazole augmentation in Taiwanese MDD outpatients with inadequate antidepressant response; Asia-Pacific practice context |
| NCT00953745 | N/A | Completed | 43 | Raclopride/F-DOPA PET + fMRI mechanistic study confirming dopaminergic pathway as primary mechanism of aripiprazole augmentation in treatment-resistant depression |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38669232 | 2024 | Systematic Review + Meta-analysis | PLoS One | First and largest meta-analysis of RCTs on aripiprazole augmentation and switching in TRD/MDD; confirmed superior efficacy over placebo with acceptable safety |
| 34986373 | 2022 | Systematic Review + NMA | J Affect Disord | Network meta-analysis comparing augmentation agents in adult TRD; aripiprazole among the most robustly studied with consistent evidence |
| 38219278 | 2024 | Systematic Review | Neuropsychopharmacol Rep | Frequentist NMA comparing brexpiprazole, aripiprazole, and placebo in Japanese MDD with inadequate ADT response; efficacy and tolerability benchmarking |
| 35510505 | 2023 | Systematic Review | Psychol Med | Comprehensive meta-analytic assessment of antipsychotics (monotherapy and adjunctive) in MDD; aripiprazole among key agents analyzed |
| 34167174 | 2021 | Systematic Review | Prim Care Companion CNS Disord | Long-term (≥6 months) efficacy and tolerability of adjunctive aripiprazole in MDD; remission rates and adverse effect incidence summarized |
| 37815563 | 2023 | Review | JAMA | Comprehensive JAMA review of bipolar disorder diagnosis and treatment, covering role of atypical antipsychotics including aripiprazole in affective episodes |
| 37149344 | 2023 | Review | Psychiatr Clin North Am | Aripiprazole identified as the most widely studied augmentation agent for TRD; practical clinical guidance on use and monitoring |
| 36855876 | 2023 | Review | Am J Psychiatry | Overview of antipsychotics in the rapidly evolving TRD landscape; aripiprazole positioned as an established augmentation option with defined evidence base |
| 36239033 | 2023 | RCT | J Psychopharmacol | Double-blind, placebo-controlled RCT of aripiprazole adjunctive therapy in MDD with somatic symptoms; EEG biomarker evidence provided alongside clinical outcomes |
| 21254788 | 2011 | Review | CNS Drugs | Foundational overview of aripiprazole's Phase 3 clinical trial program for MDD adjunctive therapy; mechanism (D2/D3 partial agonism, 5-HT1A agonism) and regulatory pathway detailed |
Saudi Arabia Market Information
Aripiprazole is currently not registered with the Saudi Food and Drug Authority (SFDA). The regulatory database query (conducted 2026-03-29) returned zero market authorizations.
For reference, aripiprazole holds regulatory approvals in multiple jurisdictions including:
- FDA (USA): Schizophrenia, Bipolar I disorder (manic/mixed episodes, adjunctive and monotherapy), Adjunctive therapy for MDD, Irritability associated with autism spectrum disorder, Tourette's disorder
- EMA (Europe): Schizophrenia, Bipolar I disorder (manic episodes)
- PMDA (Japan): Schizophrenia, Bipolar I disorder
A formal SFDA registration dossier submission would be required before clinical deployment in Saudi Arabia.
Safety Considerations
Please refer to the package insert for safety information.
Detailed SFDA-specific warning and contraindication data were unavailable in this evidence pack. Drug interaction database query returned no results. Prior to any clinical use, the full prescribing information should be reviewed. Clinicians should be aware that D2 partial agonist antipsychotics as a class carry reports of impulse control disorders (pathological gambling, hypersexuality, compulsive behaviors) — particularly relevant for the trichotillomania indication flagged at rank 7 in this evidence pack.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 double-blind RCTs, systematic reviews, and network meta-analyses provide L1 evidence for aripiprazole's efficacy and safety as adjunctive therapy for treatment-resistant major depressive disorder and as a maintenance treatment for Bipolar I disorder — both core components of major affective disorder. The FDA approval for MDD augmentation is direct regulatory validation of this prediction, making this the strongest TxGNN-predicted indication in this evidence pack.
To proceed, the following is needed:
- Submit an SFDA registration dossier to obtain Saudi Arabia market authorization (no current local approval)
- Retrieve and document full package insert / SmPC safety data (warnings, contraindications, special populations) to resolve Data Gap DG001
- Supplement MOA documentation for regulatory submission (Data Gap DG002)
- Develop a pharmacovigilance plan covering known D2 partial agonist class risks (impulse control disorders, metabolic monitoring, akathisia)
- Define patient population scope for local use: specify whether approval strategy targets TRD augmentation, bipolar maintenance, or both
- Conduct cost-effectiveness and formulary analysis for the Saudi Arabian healthcare context
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.